Nick Bakalis | Public Health | Innovative Research Award

Posted on by The Scientist

Innovative Research Award

Nick Bakalis – University of Patras

Nick Bakalis
Affiliation University of Patras
Country Greece
Scopus ID 6506484572
Documents 33
Citations 302
h-index 11
Subject Area Public Health
Event The Scientist Global Awards
ORCID 0000-0002-4786-2236

The Innovative Research Award recognizes scholarly achievement, scientific productivity, and research contributions that advance knowledge within a specific academic field. Nick Bakalis of the University of Patras has established a documented research profile in Public Health through peer-reviewed publications, citation impact, and academic engagement. His research record demonstrates sustained contributions to scientific inquiry and interdisciplinary knowledge development within public health and related domains.[1]

Abstract

This article presents an academic overview of Nick Bakalis and evaluates his suitability for recognition through the Innovative Research Award. The assessment is based on publicly available scholarly indicators, including publication output, citation performance, research visibility, and contributions to Public Health. Through peer-reviewed scientific publications and measurable scholarly impact, the researcher has contributed to advancing evidence-based knowledge and interdisciplinary scientific understanding.[1]

Keywords

Nick Bakalis, Public Health, Research Excellence, Scientific Impact, Citation Analysis, Academic Recognition, University of Patras, Scholarly Publications, Evidence-Based Research, Innovative Research Award.

Introduction

Academic awards recognize researchers who contribute significantly to scientific advancement through original investigations, scholarly publications, and measurable research impact. Within Public Health, innovative research plays a critical role in improving healthcare systems, informing policy development, and supporting evidence-based interventions. Nick Bakalis has developed a research portfolio characterized by peer-reviewed scholarship and citation visibility that reflects engagement with contemporary public health challenges.[1]

Research Profile

Nick Bakalis is affiliated with the University of Patras, Greece. His scholarly record includes 33 indexed publications, 302 citations, and an h-index of 11 according to Scopus-based metrics. These indicators suggest a sustained contribution to academic literature and demonstrate the visibility of his work within the scientific community. Research performance metrics are commonly used as one component of evaluating scholarly influence and scientific productivity.[1]

Research Contributions

The research contributions of Nick Bakalis are associated with advancing understanding in Public Health through scientific investigation, publication of peer-reviewed findings, and participation in scholarly discourse. His work contributes to the accumulation of evidence that informs future studies, supports methodological development, and encourages interdisciplinary collaboration. Research outputs that achieve citation recognition indicate relevance and utility within broader academic networks.[3]

Publications

The publication portfolio of Nick Bakalis includes articles indexed within major academic databases. Publication activity serves as an important indicator of scholarly productivity and dissemination of research findings. Indexed publications undergo editorial and peer-review processes that contribute to scientific quality assurance and academic visibility.[2]

Research Impact

Research impact may be evaluated through citation metrics, publication visibility, academic engagement, and the influence of findings on future scholarship. With 302 citations and an h-index of 11, the research record of Nick Bakalis demonstrates measurable scholarly recognition. Citation-based indicators provide evidence that published findings have been consulted and utilized by other researchers in related fields.[1]

Award Suitability

Based on documented publication activity, citation performance, scholarly visibility, and contributions to Public Health, Nick Bakalis demonstrates characteristics commonly associated with candidates for academic recognition programs. The combination of peer-reviewed publications, measurable citation impact, and sustained research engagement supports consideration for the Innovative Research Award within the framework of scientific achievement and research excellence.[4]

Conclusion

Nick Bakalis has established a documented academic profile through research contributions, publication productivity, and scholarly impact indicators within Public Health. His record reflects continued participation in scientific inquiry and knowledge dissemination. The available academic metrics and research achievements provide a basis for recognition through the Innovative Research Award and highlight the importance of sustained scholarly contributions to advancing public health research.[1]

References

  1. Elsevier. (2026). Scopus author details: Nick Bakalis, Author ID 6506484572. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6506484572
  2. Nursing in Critical Care. (2026). Expert Consensus on Key Attributes of Nurses in Resuscitation Teams: Findings From a Delphi Study. https://doi.org/10.1111/nicc.70506
  3. ORCID. (2026). Researcher Identifier Record: Nick Bakalis.
    https://orcid.org/0000-0002-4786-2236
  4. The Scientist Global Awards. (2026). Academic Recognition and Award Program Information.
    https://thescientists.net/

Ilias Karaiskos | Public Health | Best Researcher Award

Posted on by The Scientist

Dr. Ilias Karaiskos | Public Health | Best Researcher Award

1st Department of Internal Medicine-Infectious Diseases |  Hygeia hospital, Athens | Greece

Dr. Ilias Karaiskos is a distinguished physician and clinical researcher specializing in internal medicine and infectious diseases at the 1st Department of Internal Medicine, Hygeia General Hospital, Athens, Greece. Working under the leadership of Professor H. Giamarellou, he has contributed extensively to the management of complex infections, infection control, and antimicrobial stewardship within one of Greece’s most advanced and internationally accredited healthcare institutions. Dr. Karaiskos’s research focuses on antimicrobial pharmacokinetics, multidrug-resistant pathogens, and optimized antibiotic therapy in critically ill patients. His doctoral work on the pharmacokinetics of colistin significantly influenced global clinical practice, forming part of the International Consensus Guidelines for the Optimal Use of Polymyxins. Recognized by the Hellenic Society for Infectious Diseases with the Best PhD Award (2015), his research has shaped antibiotic dosing strategies that improve patient outcomes and reduce antimicrobial resistance. With over 80 peer-reviewed publications and an h-index of 39, Dr. Karaiskos has amassed more than 5,600 citations through collaborative studies with leading European and global research consortia, including the EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). His recent works address the efficacy of novel β-lactamase inhibitors, pharmacokinetics of ceftazidime-avibactam in renal replacement therapy, and strategies for infection control in intensive care settings. Through his clinical leadership, academic collaborations, and evidence-based research, Dr. Karaiskos continues to advance the global fight against antimicrobial resistance, shaping policies and treatment guidelines that enhance the quality and safety of infectious disease management worldwide.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate

Featured Publications

  1. Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Karaiskos, I., … (2019). International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and others. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(1), 10–39. Citations: 949

  2. Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Karaiskos, I., … (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrobial Agents and Chemotherapy, 53(8), 3430–3436. Citations: 637

  3. Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P. R., Viale, P., Karaiskos, I., … (2017). Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. The Lancet Infectious Diseases, 17(7), 726–734. Citations: 545

  4. Karaiskos, I., & Giamarellou, H. (2014). Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: Current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy, 15(10), 1351–1370. Citations: 435

  5. Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019). The “old” and the “new” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Frontiers in Public Health, 7, 151. Citations: 328